GenPharm International Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GenPharm International Inc.
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Admedus and its product mix was an unfolding success story – and still is, due to a restructuring of activities and a resetting of aims that have ensured the Australia-US tissue engineering company does not miss out on the opportunities it has crafted for itself. Chairman and interim CEO Wayne Paterson explains what changes were required and why.
There are not many companies whose R&D business model combines immunotherapies and a medtech cardio franchise, but for Australia’s Admedus it’s a plan that is working so far. And more original science could be added to the portfolio as the company moves increasingly away from its S&D roots.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.